TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as Adjuvant Treatment for Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Subjects whose depressive symptoms have not remitted during their participation in the Pharmacokinetics and Pharmacodynamics of Citalopram and Escitalopram study or the Pharmacokinetics and Pharmacodynamics of Duloxetine study~* Must be able to continue to take same dose of duloxetine through the course of the study~Exclusion Criteria~* A history of failure for respond to Electroconvulsive Therapy (ECT)~* Any metal in the head (except in mouth)~* Implanted medication pump or cardiac pacemaker~* Have had prior brain surgery~* Have unprovoked seizure disorder or family history of treatment resistant epilepsy~* Pregnancy~* Psychiatric hospitalization within the past two weeks~* Suicide attempt with hospitalization within past three months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Repetitive Transcranial Magnetic Stimulation (Type: EXPERIMENTAL): All subjects will receive 10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for a fixed-flexible period of 5 treatments per week for up to 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Roles of Estrogen and Progesterone in Heart Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy postmenopausal woman~* Body mass index less than 30~* Practices normal eating habits~* Stops hormone replacement therapy at least 6 months prior to study entry~Exclusion Criteria:~* Currently taking hormone replacement therapy~* History of cardiovascular disease~* Family history of coronary artery disease~* Recent history of smoking, high blood pressure, or hyperlipidemia

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- estrogen plus progesterone (Type: EXPERIMENTAL): Hormone replacement therapy (HRT): estrogen plus progesterone
- estrogen plus placebo (Type: ACTIVE_COMPARATOR): Hormone replacement therapy (HRT): estrogen plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult men and women who are 18 years of age or older.~* Diagnosis of plaque-type psoriasis is required to be confirmed by clinical criteria.~* Subjects must be in general good health with no other skin disease, disease state or physical condition which would impair evaluation of psoriasis or which would increase their health risk by study participation.~* Subjects must be willing to receive topical capsaicin weekly for 6 weeks and must be willing to undergo 3mm punch biopsies at baseline and at week 6.~* Subjects may not receive any systemic therapies during the study.~* Subjects are required to complete a 4 week washout period from any systemic medication and/or phototherapy prior to enrolling in the study.~* Stable use of moisturizers will be allowed provided that use has been stable for at least 14 days.~* Women of child bearing age will be required to have a negative pregnancy test in order to enroll in the study and will be required to maintain adequate birth control throughout the study.~Exclusion Criteria:~* Subjects who are unable to complete the required measures.~* Subjects diagnosed with other skin diseases that would affect the measurement of cutaneous blood flow.~* Subjects with any history of any disease associated with neuropathy, including diabetes, alcoholism, uremia, HIV infection, hypothyroidism, or cancer chemotherapy.~* Subjects who are currently enrolled in any investigational study in which the subject is receiving any type of drug, biologic, or non-drug therapy and subjects undergoing treatment with another investigational drug or approved therapy for investigational use within 28 days prior to investigational drug administration.~* Subjects who have used any topical therapy for psoriasis or other skin diseases in the past 7 days.~* Subjects receiving any of the following treatments or agents within the 28 days prior to investigational drug administration will be excluded: systemic retinoids, systemic steroids, methotrexate, cyclosporine, azathioprine, thioguanine, etanercept, efalizumab, infliximab, adalimumab or mofetil or other systemic immunosuppressant, and phototherapy, including Ultraviolet B (UVB) and Psoralen + Ultraviolet A (PUVA).~* Subjects with a known allergy to capsaicin.~* Children less than 18 years of age.~* Pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Study subjects will be patients with chronic plaque-type psoriasis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fenretinide in Healthy Young Women at Genetic and Familial Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 20-46 years old women with a known BRCA ½ mutation or with a risk of being a mutation carrier ≥20%.~2. Performance status =0~3. Willingness to avoid pregnancy during treatment and 12 months after drug cessation~4. No clinical and radiological evidence of breast cancer and ovarian disease~5. Signed informed consent~Exclusion Criteria:~1. History of breast cancer or any other malignancy with the exclusion of CIN and non-melanoma skin cancer~2. Child bearing or breast feeding~3. Genetic test result (BRCA)=true negative~4. Blood test alterations (grade ≥2 based on the NCI Common Toxicity Criteria)~5. Previous or concurrent use of SERMs, e.g. tamoxifen (for more than 12 months; if less, a two-months wash-out is required before entering the study)~6. Severe psychiatric disorders or inability to comply to the protocol procedures~7. Any other factor that, at the investigator's discretion, contraindicates the use of fenretinide

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- Fenretinide (Type: EXPERIMENTAL): 100mg: 2cps/day for 5 years followed by
- Placebo (Type: PLACEBO_COMPARATOR): matched placebo 2 cps/day for 5 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients with primary open-glaucoma (POAG), primary angle-closure glaucoma (PACG), pseudoexfoliation, pigmentary, traumatic, uveitic or neovascular glaucoma~Exclusion Criteria:~1. Age ≤ 18 years old.~2. Any type of glaucoma other than those listed in the inclusion criteria.~3. Less than 3 months of other ocular surgery.~4. Active thyroid-related immune orbitopathy, carotid-cavernous fistula, Sturge Weber syndrome, orbital tumors or orbital congestive disease.~5. Patients with connective tissue disorder.~6. Patients with congenital or developmental glaucoma.~7. Patients with severe dry eye syndrome.~8. Patients with any surgical procedure involving revision, removal, or change of the existing glaucoma tube shunt.~9. Patients undergoing any surgical concomitant surgical procedure involving the posterior segment.~10. Patients with active scleritis, history of ocular trauma including chemical burn, chronic ocular inflammatory disease, or ocular surface disease.~11. Patients with any prior history of allergy to the active compound.~12. Pregnancy or breast-feeding.~13. Patients enrolled in other prospective clinical trials.~14. Patients that plan to use contact lens after surgery.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KeraSys Tissue Patch Graft (Type: ACTIVE_COMPARATOR): 20 patients needing a Molteno 3 glaucoma drainage shunt implant will receive the KeraSys patch graft
- Tutoplast tissue patch graft (Type: ACTIVE_COMPARATOR): 20 patients need Molteno 3 glaucoma drainage surgery will receive tutoplast patch graft

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) 0 or 1.~* Histologically or cytologically proven diagnosis of breast cancer with evidence of locally recurrent or metastatic disease.~* Documentation of estrogen and progestin receptor (ER/PR) negative status and HER2/neu receptor negative status (ie, FISH negative or immunohistochemistry 0 or +1).~* Obtained complete response or Good partial response after first line chemotherapy.~* Normal organ function required prior to study entry.~* Willingness to comply with treatment plans and other study procedures.~Exclusion Criteria:~* Uncontrolled central nervous system (CNS) involvement with disease~* Fertile women unwilling to use contraceptive techniques during treatment~* Females who are pregnant~* Organ dysfunction.~* Patients may not be receiving any other investigational agents.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Metastatic triple negative breast cancer (Type: EXPERIMENTAL): Abraxane,Cyclophosphamide,Carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> or equal to 18.~* On mechanical ventilation using a volume-controlled mode.~* Admitted to Boston Medical Center Surgical, Medical, or Coronary Intensive Care Unit.~* Meets American-European Consensus Criteria for Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome.~* Required mechanical ventilator for less than 14 days.~* Met ARDS or ALI criteria for less than 7 days prior to enrollment.~* Assent of primary care team~Exclusion Criteria:~* Do not resuscitate order.~* Increased intracranial pressure.~* Pregnancy (urine pregnancy test for all women of child-bearing age).~* Planned transport out of ICU during planned study protocol.~* Coagulopathy (INR\>2.0 or PTT \>50).~* Severe thrombocytopenia (platelets \<20,000).~* History of obstructive lung disease (asthma and/or COPD).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- low-tidal-volume ventilation (Type: ACTIVE_COMPARATOR): Goal tidal volume is 6 cc/kg ideal body weight.
- APRV (Type: EXPERIMENTAL): APRV allows spontaneous breathing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Mobility Devices on Nursing Compliance With Mobility Protocols

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>18 years of age~* On the ventilator for \> 48 hours~* Mobility score \> 3~Exclusion Criteria:~* \> 220 lbs~* Limb amputees~* Prisoners~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Front Wheeled Walker (Type: ACTIVE_COMPARATOR): The Front Wheeled Walker is a standard walker that is used to assist patients while walking.
- Rifton Gait Trainer (Type: ACTIVE_COMPARATOR): The Rifton Gait Trainer is used to assist patients while walking. It includes a harness to support the patient and prevent falls.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Rehabilitation in Operation for Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Performance status 0-2 (WHO)~* Living in the City of Copenhagen or surrounding Municipalities~* Ability to read and understand Danish~* Approval by primary surgeon~Exclusion Criteria:~* Presence of metastatic disease or surgical inoperability~* Diagnosis of Lung Cancer not verified by histological diagnosis~* Cardiac disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. Experimental (Type: EXPERIMENTAL): Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery.
- 2. Experimental (Type: EXPERIMENTAL): Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery.
- 3. Experimental (Type: EXPERIMENTAL): Exercise in a team initiated two weeks after surgery.
- 4. Usual care (Type: OTHER): Exercise in a team initiated six weeks after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Outreach for Patients That Are Newly Eligible for Colorectal Cancer Screening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient of Northwestern Medical Faculty Foundation General Internal Medicine~* Patient has a scheduled appointment with a GIM physician in the next several weeks~* Patient will be 50 years old at the time of this appointment~* Patient is male or female~Exclusion Criteria:~* This is the first time the patient is seen in the NMFF GIM clinic~* There is a prior completion of CRC screening noted in EHR.~* There is a prior order placed for CRC screening in EHR.~* Patient has a history of CRC~* Patient has a diagnosis of ulcerative colitis, inflammatory bowel disease, Crohn's Disease, or documented colectomy.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Usual Care. Participants in this arm will receive Usual care until outcome assessment is performed at 6 months following randomization. At that time, they will be sent a letter reminding them to obtain the ordered preventative service test, however no further outcomes will be assessed. Thus, during the course of the study, all participants in this arm will have solely received usual care.
- Behavioral: Letter Only (Type: EXPERIMENTAL): Behavioral: Letter Only Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
- Behavioral: Letter and Educational DVD (Type: EXPERIMENTAL): Behavioral: Letter and Educational DVD Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study on Fistuloplasty Using Flow Measurement Guidance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant female subjects, between the ages of 18 and 80 at the time of enrollment.~* Subjects referred to us from the Dialysis units located in the study centres for clinically indicated fistulogram and fistula treatment.~* Written informed consent to participate in the study.~* Ability to comply with the requirements of the study procedures~Exclusion Criteria:~* Significant coagulopathy that cannot be adequately corrected.~* Subjects who participated in an active stage of any drug, intervention or treatment trial within 30 days of enrollment.~* Subjects with preexisting conditions, which, in the opinion of the investigator, interfere with the conduct of the study. Patients will only be excluded on this basis following discussion with another interventional radiologist and the referring nephrologist.~* Subjects who are uncooperative or cannot follow instructions.~* Mental state that may preclude completion of the study procedure or ability to obtain informed consent.~* Pregnant or nursing female subjects.~* Patients whose fistulae have never become functional.~* Patients with PTFE grafts/non-native fistulae~* Patients who have had previous stenting of fistulae

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Transonics Arm (Type: EXPERIMENTAL): Intervention will be guided by flow through the fistula as guided by Transonics flow measurements
- Control arm (Type: NO_INTERVENTION): Patient will undergo normal fistula intervention guided only by angiographic assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including any of the following histologic subtypes:~  * Squamous cell carcinoma~ * Adenocarcinoma~ * Large cell undifferentiated carcinoma~* Stage II or IIIA disease~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral Computerized Axial Tomography (CT) scan~* No tumor involving the superior sulcus (e.g., Pancoast tumor)~* Karnofsky performance status 70-100%~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Creatinine ≤ 2 mg/dL~* Bilirubin \< 2 mg/dL~* Aspartate aminotransferase (AST) \< 3 times upper limit of normal~Exclusion Criteria:~* Pregnant or nursing~  * No nursing during and for ≥ 4 weeks after completion of study treatment~* Positive pregnancy test~* Fertile female patients must use 2 effective methods of contraception 4 weeks before, during, and for 4 weeks after completion of study treatment~* Fertile male patients must use effective barrier contraception during and for 4 weeks after completion of study treatment~* Blood, sperm, or ova donation during study treatment~* Post obstructive pneumonia~* Other serious infection or medical illness that would preclude study participation~* Other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other malignancy that is unlikely to affect survival for the next 3 years~* Less than 5 years since prior resection of lung disease~* Prior systemic chemotherapy or radiotherapy for non-small cell lung cancer (NSCLC)~* Other concurrent chemotherapy or radiotherapy~* Concurrent hormonal therapy or immunotherapy~* Other concurrent anticancer therapy~* Other concurrent investigational agents~* Concurrent participation in another clinical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Chemotherapy treatment (carboplatin, gemcitabine and thalidomide) every 21 days for 3 courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy